Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer
Top Cited Papers
- 5 May 2010
- journal article
- review article
- Published by American Medical Association (AMA) in Jama-Journal Of The American Medical Association
- Vol. 303 (17), 1729-1737
- https://doi.org/10.1001/jama.2010.534
Abstract
Context Despite potentially curative resection of stomach cancer, 50% to 90% of patients die of disease relapse. Numerous randomized clinical trials (RCTs) have compared surgery alone with adjuvant chemotherapy, but definitive evidence is lacking. Objectives To perform an individual patient-level meta-analysis of all RCTs to quantify the potential benefit of chemotherapy after complete resection over surgery alone in terms of overall survival and disease-free survival, and to further study the role of regimens, including monochemotherapy; combined chemotherapy with fluorouracil derivatives, mitomycin C, and other therapies but no anthracyclines; combined chemotherapy with fluorouracil derivatives, mitomycin C, and anthracyclines; and other treatments. Data Sources Data from all RCTs comparing adjuvant chemotherapy with surgery alone in patients with resectable gastric cancer. We searched MEDLINE (up to 2009), the Cochrane Central Register of Controlled Trials, the National Institutes of Health trial registry, and published proceedings from major oncologic and gastrointestinal cancer meetings. Study Selection All RCTs closed to patient recruitment before 2004 were eligible. Trials testing radiotherapy; neoadjuvant, perioperative, or intraperitoneal chemotherapy; or immunotherapy were excluded. Thirty-one eligible trials (6390 patients) were identified. Data Extraction As of 2010, individual patient data were available from 17 trials (3838 patients representing 60% of the targeted data) with a median follow-up exceeding 7 years. Results There were 1000 deaths among 1924 patients assigned to chemotherapy groups and 1067 deaths among 1857 patients assigned to surgery-only groups. Adjuvant chemotherapy was associated with a statistically significant benefit in terms of overall survival (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.76-0.90; P < .001) and disease-free survival (HR, 0.82; 95% CI, 0.75-0.90; P < .001). There was no significant heterogeneity for overall survival across RCTs (P = .52) or the 4 regimen groups (P = .13). Five-year overall survival increased from 49.6% to 55.3% with chemotherapy. Conclusion Among the RCTs included, postoperative adjuvant chemotherapy based on fluorouracil regimens was associated with reduced risk of death in gastric cancer compared with surgery alone.Keywords
This publication has 40 references indexed in Scilit:
- The Role of Postoperative Adjuvant Chemotherapy Following Curative Resection for Gastric Cancer: A Meta-AnalysisCancer Investigation, 2008
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineNew England Journal of Medicine, 2007
- Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)Annals of Oncology, 2007
- Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801)Annals of Oncology, 2005
- Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancerGastric Cancer, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Meta-analyses of randomised clinical trials in oncologyThe Lancet Oncology, 2001
- A Randomized Trial Comparing Adjuvant Fluorouracil, Epirubicin, and Mitomycin with No Treatment in Operable Gastric CancerChemotherapy, 1996
- Adjuvant chemotherapy for resectable gastric cancer: A preliminary reportJournal of Surgical Oncology, 1994
- Positive results of adjuvant mitomycin-C in resected gastric cancer: A randomised trial on 134 patientsEuropean Journal of Cancer, 1993